Arbutus Biopharma Corp (NASDAQ: ABUS) is 3.06% higher on its value in year-to-date trading and has touched a low of $2.30 and a high of $4.72 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ABUS stock was last observed hovering at around $3.46 in the last trading session, with the day’s loss setting it -0.09%.
Currently trading at $3.37, the stock is -0.41% and 1.20% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.31 million and changing -2.60% at the moment leaves the stock -6.10% off its SMA200. ABUS registered 24.35% gain for a year compared to 6-month loss of -15.54%.
The stock witnessed a 0.30% gain in the last 1 month and extending the period to 3 months gives it a -2.60%, and is 0.00% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.14% over the week and 4.52% over the month.
Arbutus Biopharma Corp (ABUS) has around 73 employees, a market worth around $638.59M and $6.74M in sales. Profit margin for the company is -1137.64%. Distance from 52-week low is 46.52% and -28.68% from its 52-week high. The company has generated returns on investments over the last 12 months (-67.77%).
with sales reaching $2.21M over the same period.The EPS is expected to grow by 12.50% this year, but quarterly earnings will post -64.58% year-over-year. Quarterly sales are estimated to shrink -24.18% in year-over-year returns.
The shares outstanding are 189.44M, and float is at 147.08M with Short Float at 4.90%.
The top institutional shareholder in the company is MORGAN STANLEY with over 20.96 million shares valued at $64.77 million. The investor’s holdings represent 11.9346 of the ABUS Shares outstanding. As of 2024-06-30, the second largest holder is WHITEFORT CAPITAL MANAGEMENT, LP with 12.87 million shares valued at $39.76 million to account for 6.8432 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 11.55 million shares representing 6.5777 and valued at over $35.7 million, while TWO SEAS CAPITAL LP holds 4.5584 of the shares totaling 8.57 million with a market value of $26.49 million.
Arbutus Biopharma Corp (ABUS) Insider Activity
The most recent transaction is an insider sale by HASTINGS DAVID C, the company’s Chief Financial Officer. SEC filings show that HASTINGS DAVID C sold 22,183 shares of the company’s common stock on Feb 04 ’25 at a price of $3.28 per share for a total of $72827.0. Following the sale, the insider now owns 0.16 million shares.
Arbutus Biopharma Corp disclosed in a document filed with the SEC on Feb 04 ’25 that Sims Karen (Chief Medical Officer) sold a total of 19,348 shares of the company’s common stock. The trade occurred on Feb 04 ’25 and was made at $3.28 per share for $63519.0. Following the transaction, the insider now directly holds 0.11 million shares of the ABUS stock.
Still, SEC filings show that on Feb 04 ’25, McElhaugh Michael J. (Interim President & CEO) disposed off 23,790 shares at an average price of $3.28 for $78103.0. The insider now directly holds 1,481,003 shares of Arbutus Biopharma Corp (ABUS).
